A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Inclusion Criteria:

1. Participants of any sex and gender must be ≥ 18 years old, or older, at the time ofsigning the informed consent.

2. Participants with CKD and eGFR ≥ 30 and < 90 mL/min/1.73 m2 at screening

3. Urine albumin creatinine ratio > 200 mg/g (22.6 mg/mmol) and < 5000 mg/g (565mg/mmol) at screening

4. Participants with history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg atthe randomisation visit

5. Stable and maximum tolerated dose of an ACE inhibitor or an ARB (not both) for atleast 4 weeks prior to Screening Visit

6. Central laboratory serum potassium must meet the following criteria at the ScreeningVisit, based on screening eGFR:

• for participants with screening eGFR ≥ 45 mL/min/1.73 m2, potassium must be ≥ 3.0 and ≤ 4.8 mmol/L at the Screening Visit

• for participants with screening eGFR < 45 mL/min/1.73 m2, potassium must be ≥ 3.0 and ≤ 4.5 mmol/L at the Screening Visit

Exclusion Criteria:

1. Systolic blood pressure > 180 mmHg, or DBP > 110 mmHg at screening.

2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months atscreening.

3. Serum sodium < 135 mmol/L at the Screening Visit, determined as per centrallaboratory.

4. Diabetes mellitus:

(a) T1DM at Screening Visit: (i) For US only: patients with T1DM treated with SGLT2ifor at least 4 months, without DKA during that period, and who have experience withketone monitoring are eligible for inclusion.

(ii) For Japan only: patients with T1DM treated with dapagliflozin 10 mg for atleast 4 months, without DKA during the period of dapagliflozin treatment areeligible for inclusion.

(b) Uncontrolled T2DM at screening: HbA1C > 10.5% (> 91 mmol/mol).

5. New York Heart Association functional HF class IV at screening.

6. Stroke, transient ischaemic cerebral attack, valve implantation or valvereplacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, orhospitalisation for worsening heart failure within previous 3 months prior torandomisation.

7. Any dialysis (including for acute kidney injury) within 3 months prior to ScreeningVisit.

8. Any acute kidney injury within 3 months prior to the Screening Visit

9. History of organ transplant or bone marrow transplant, or planned organ transplantwithin 6 months following randomisation (including kidney transplant).

10. History or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2inhibitor (eg, empagliflozin) or ASI.

11. Any clinical condition requiring systemic immunosuppression therapy other thanstable maintenance therapy for at least 3 months prior to Visit 1.

12. Any use of mineralocorticoid receptor antagonists (such as spironolactone,eplerenone, or finerenone), potassium-sparing diuretics (such as triamterene oramiloride), or potassium binders (such as sodium zirconium cyclosilicate, patiromer,or sodium polystyrene sulfonate) within 4 weeks prior to screening.